Holen Sie sich die Stockscreener-App
25.80
0.39%
0.10
Handel nachbörslich:
25.86
0.06
+0.23%
Schlusskurs vom Vortag:
$25.70
Offen:
$25.76
24-Stunden-Volumen:
3.35M
Relative Volume:
1.59
Marktkapitalisierung:
$11.41B
Einnahmen:
$2.24B
Nettoeinkommen (Verlust:
$673.24M
KGV:
229.33
EPS:
0.1125
Netto-Cashflow:
$2.67B
1W Leistung:
-2.12%
1M Leistung:
-7.79%
6M Leistung:
-5.39%
1J Leistung:
-3.01%
1-Tages-Spanne:
$25.51
$25.94
1-Wochen-Bereich:
$25.10
$26.41
52-Wochen-Spanne:
$25.10
$31.66
Royalty Pharma Plc Stock (RPRX) Company Profile
Firmenname
Royalty Pharma Plc
Sektor
Branche
Telefon
(212) 883-0200
Adresse
110 EAST 59TH STREET, NEW YORK, NY
Vergleichen Sie RPRX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| RPRX | 25.80 | 11.41B | 2.24B | 673.24M | 2.67B | 0.1125 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Royalty Pharma Plc Stock (RPRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-06-03 | Herabstufung | UBS | Buy → Neutral |
| 2022-06-14 | Fortgesetzt | UBS | Buy |
| 2022-05-13 | Eingeleitet | Scotiabank | Sector Outperform |
| 2022-04-27 | Eingeleitet | Goldman | Buy |
| 2022-04-14 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-04-06 | Fortgesetzt | Morgan Stanley | Overweight |
| 2021-10-29 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-07-30 | Eingeleitet | Tigress Financial | Buy |
| 2020-11-09 | Hochstufung | UBS | Neutral → Buy |
| 2020-07-14 | Eingeleitet | Evercore ISI | In-line |
| 2020-07-13 | Eingeleitet | BofA Securities | Buy |
| 2020-07-13 | Eingeleitet | Citigroup | Neutral |
| 2020-07-13 | Eingeleitet | Cowen | Outperform |
| 2020-07-13 | Eingeleitet | Goldman | Neutral |
| 2020-07-13 | Eingeleitet | JP Morgan | Neutral |
| 2020-07-13 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2020-07-13 | Eingeleitet | SunTrust | Buy |
| 2020-07-13 | Eingeleitet | UBS | Neutral |
Alle ansehen
Royalty Pharma Plc Aktie (RPRX) Neueste Nachrichten
Royalty Pharma plc (NASDAQ:RPRX) Stake Reduced by Amalgamated Bank - MarketBeat
Undercovered Dozen: Aurora Cannabis, FREYR Battery, Royalty Pharma, Talos Energy + - Seeking Alpha
Royalty Pharma stock hits 52-week low at $25.2 amid market shifts - Investing.com India
Royalty Pharma (NASDAQ:RPRX) Sets New 52-Week LowTime to Sell? - MarketBeat
Simplify Asset Management Inc. Increases Position in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
(RPRX) Technical Data - Stock Traders Daily
Royalty Pharma Announces Inaugural Prize for Impact in Healthcare - The Manila Times
Royalty Pharma Awards Inaugural Healthcare Prize to Michael Milken for Cancer Research Impact | RPRX Stock News - StockTitan
3 High-Yield Dividend Stocks You Can Buy With $130 Now and Hold at Least a Decade - The Motley Fool
Ex-Dividend Reminder: Cencora, Royalty Pharma and Brookline Bancorp - Nasdaq
Solid Earnings May Not Tell The Whole Story For Royalty Pharma (NASDAQ:RPRX) - Simply Wall St
Royalty Pharma's (NASDAQ:RPRX) Profits May Not Reveal Underlying Issues - Yahoo Finance
Syndax shares slide despite pivotal trial success - The Pharma Letter
New South Capital Management Inc. Has $69.77 Million Stake in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Baillie Gifford & Co. Reduces Holdings in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Los Angeles Capital Management LLC Lowers Position in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Van ECK Associates Corp Boosts Stock Position in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Royalty Pharma Q3 2024 Earnings Preview - MSN
Summit Global Investments Purchases New Position in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Royalty Pharma (NASDAQ:RPRX) Sees Unusually-High Trading VolumeHere's Why - MarketBeat
Royalty Pharma plc (NASDAQ:RPRX) Shares Sold by Executive Wealth Management LLC - MarketBeat
Royalty Pharma Stock: Massive Opportunity Ahead (NASDAQ:RPRX) - Seeking Alpha
Morgan Stanley's Strategic Reduction in Royalty Pharma PLC Holdi - GuruFocus.com
Royalty Pharma plc (NASDAQ:RPRX) Q3 2024 Earnings Call Transcript - Insider Monkey
Royalty Pharma to Acquire Royalty Interest in Geron's RYTELO for $125 Million - The Manila Times
Royalty Pharma plc (RPRX) to Acquire Royalty Interest in Geron’s (GERN) RYTELO for $125M - StreetInsider.com
Royalty Pharma to Acquire Royalty Interest in Geron’s RYTELO for $125 Million - StockTitan
Royalty Pharma plc (NASDAQ:RPRX) Shares Acquired by Robeco Institutional Asset Management B.V. - MarketBeat
Royalty Pharma PLC (RPRX) Q3 2024 Earnings Call Highlights: Strong Growth and Strategic Acquisitions - Investing.com Canada
Royalty Pharma PLC (RPRX): A Strategic SWOT Insight - Yahoo Finance
Royalty Pharma Reports Strong Q3 2024 Results - TipRanks
Compared to Estimates, Royalty Pharma (RPRX) Q3 Earnings: A Look at Key Metrics - Yahoo Finance
Earnings call: Royalty Pharma reports robust Q3 growth, raises guidance By Investing.com - Investing.com Nigeria
Royalty Pharma reports robust Q3 growth, raises guidance By Investing.com - ழ தொலைக்காட்சி
Earnings call: Royalty Pharma reports robust Q3 growth, raises guidance - Investing.com
Royalty Pharma Reports Third Quarter 2024 Results - ForexTV.com
Royalty Pharma plc Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Royalty Pharma Q3 Soars: 15% Revenue Growth, $1.2B Deployment Drives Guidance Boost | RPRX Stock News - StockTitan
Tesla Inc (TSLA-Q) QuotePress Release - The Globe and Mail
River Road Asset Management LLC Has $13.30 Million Stock Holdings in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Finance Watch: Syndax Raises $350m, KalVista Gets $100m In Royalty Deals - Citeline
Insights Ahead: Royalty Pharma's Quarterly Earnings - Benzinga
Royalty Pharma (NASDAQ:RPRX) Raised to “Buy” at StockNews.com - Defense World
Syndax agrees funding with Royalty Pharma for Niktimvo US sales - Yahoo Finance
Royalty Pharma plc and Syndax Pharmaceuticals Enter into $350 Million Royalty Funding Agreement for Niktimvo - Marketscreener.com
Royalty Pharma (NASDAQ:RPRX) Upgraded at StockNews.com - MarketBeat
Royalty Pharma and Syndax Pharmaceuticals Enter Into $350 Million Royalty Funding Agreement for Niktimvo - The Manila Times
Syndax secures $350 million in royalty funding from Royalty Pharma By Investing.com - Investing.com UK
Syndax Pharmaceuticals and Royalty Pharma Enter into $350 Million Royalty Funding Agreement for Niktimvo™ - StockTitan
With 72% ownership, Royalty Pharma plc (NASDAQ:RPRX) boasts of strong institutional backing - Simply Wall St
abrdn plc Reduces Stock Holdings in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Finanzdaten der Royalty Pharma Plc-Aktie (RPRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.66%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):